Rare diseases
Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs
News
Rare diseases
Sciensus names Julie Gosper as Managing Director, Rare & Specialty, to accelerate biopharma access to European markets
Thought Leadership
Rare diseases
From innovation to access: securing the last mile in rare disease
Blogs
Rare diseases
Patient engagement and in‑market support: best practices post‑approval
Blogs
Rare diseases
Early/expanded access programmes: Making rare treatments accessible ethically and efficiently in Europe
Thought Leadership
Rare diseases
Rare disease launch insights report
Events
Rare diseases
We’re speaking at the WODC EU 2025
Thought Leadership
Rare diseases
Empowering the patient voice
Events
Rare diseases
We’re speaking at the Rare Trials Summit 2025
Case Studies
Rare diseases
How Sciensus supported the launch and distribution of a breakthrough therapy in Europe and beyond